Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | BCR | P11274 | 4/20 | 0.40 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662773 | 0.90 | HRH3 (0.43) | HRH3GRM5ABL1BCRCCNC | |
| SCHEMBL3660847 | 0.84 | HRH3 (0.44) | HRH3GRM5ABL1BCRCCNC | |
| SCHEMBL3725926 | 0.82 | PARP1 (0.40) | HRH3 | |
| SCHEMBL3656411 | 0.82 | ABL1 (0.44) | HRH3ABL1BCRCCNCCDK8 | |
| SCHEMBL4175579 | 0.80 | POLB (0.46) | GRM5ABL1BCRCCNCCDK8 | |
| SCHEMBL3728093 | 0.78 | F12 (0.48) | HRH3ABL1BCRSLC6A7MET | |
| SCHEMBL3659562 | 0.78 | HRH3 (0.45) | HRH3GRM5ABL1BCRSLC6A7 | |
| SCHEMBL3717402 | 0.78 | BMPR1B (0.45) | GRM5CCNCCDK8 | |
| SCHEMBL13743227 | 0.78 | HRH3 (0.53) | HRH3CCNCCDK8SLC6A7CHRNA7 | |
| SCHEMBL3658377 | 0.77 | ABL1 (0.45) | HRH3ABL1BCRSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | HRH3 453/4885GRM5 4235/4885ABL1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.